Quanterix(US:QTRX)2020-03-10 16:10Financial Performance - Quanterix Q4 2019 revenue reached $15.9 million, a 46% increase compared to $10.9 million in Q4 2018[7, 79] - Full year 2019 revenue was $56.7 million, representing a 51% growth from $37.6 million in 2018[7, 79] - Consumables revenue showed significant growth, with full year 2019 consumables revenue increasing by 86%[6, 7] - Adjusted gross margin for full year 2019 was 49.7%, an increase of 380 bps compared to 45.9% in 2018[7] Product and Market Growth - Instruments revenue grew by 55% for the full year 2019[7, 9] - Neurology showed a growth of 121%[10] - The company raised approximately $120 million in growth capital[6] Technology and Innovation - Simoa technology enables a +3,000X increase in sensitivity[18] - The company aims for a 100x sensitivity increase by the end of 2021[62] - Nf-L publications increased significantly, demonstrating clinical utility in disease activity monitoring and drug efficacy[6, 44] Strategic Focus - The company is focused on neurology and oncology, with strategic mergers and acquisitions to expand capabilities[6, 62] - Quanterix has a methodical market penetration strategy targeting both research and diagnostics markets, with an aspiration to disrupt the $40B+ diagnostics market[25, 27, 67] - The company aims to achieve 50%+ utilization and 50% HD-X installed base by the end of 2020[62]